A team of researchers has successfully created more effective immune cells that can fight cancer without damaging healthy ...

Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and predicts that a treatment could be approved in the next 5-10 years.

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with ...

The research groups led by Wolfgang Kastenmüller and Georg Gasteiger employed innovative microscopy techniques to observe how ...

For the first time, researchers have used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to accurately model a patient's response to CAR T cell therapy in real time.

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors -- a smart fighter that destroys cancer cells for days without tiring. Biomedical engineers have made this ...

Researchers with City of Hope and MSK have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient’s likely response to chimeric antigen receptor (CAR) T cell therapy ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

In cultures of both human cells and living mice, engineered regulatory T cells were able to simmer down gluten-reactive effector T cells that cause the characteristic autoimmune response seen in ...